paroxetine has been researched along with Diabetes Mellitus, Type 2 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, P; Hao, L; He, X; Jia, Y; Liang, Z; Tong, B; Yang, F; Yuan, J; Zhao, L; Zhu, R | 1 |
| Azoulay, L; Cao, TXD; Fergusson, E; Filliter, C; Montastruc, F; Rej, S; Renoux, C; Yu, OHY | 1 |
| Abbaszadegan, MR; Ahmadimanesh, M; Hedayati, N; Jamialahmadi, T; Sahebkar, A; Yazdian-Robati, R | 1 |
| Allen, J; Bibeau, KB; Gooden, KM; Heim, JM; Irizarry, MC; Pan, X; Sampson, T; Wood, J | 1 |
| Gutierrez, AM; Mohammadi, M; Weber, M | 1 |
| De Koning, FH; Derijks, HJ; Egberts, AC; Heerdink, ER; Janknegt, R; Krekels, MM; Looij, BJ | 1 |
| Eriksson, JG; Paile-Hyvärinen, M; Wahlbeck, K | 2 |
| Deuschle, M; Gilles, M; Heuser, I; Lederbogen, F; Weber-Hamann, B | 1 |
1 review(s) available for paroxetine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors.
Topics: Citalopram; Diabetes Mellitus, Type 2; DNA Damage; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2021 |
4 trial(s) available for paroxetine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine | 2021 |
Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, Type 2; Female; Humans; Middle Aged; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 2003 |
Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hydrocortisone; Hypoglycemic Agents; Hypothalamo-Hypophyseal System; Insulin; Insulin Resistance; Male; Middle Aged; Paroxetine; Pituitary-Adrenal System; Risk Factors; Saliva | 2006 |
Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial.
Topics: Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Health Status Indicators; Humans; Male; Mental Health; Middle Aged; Paroxetine; Quality of Life | 2007 |
4 other study(ies) available for paroxetine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Diabetes Mellitus, Type 2; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2022 |
Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insurance, Health; Male; Middle Aged; Paroxetine; Pravastatin; Retrospective Studies; Risk Assessment; Young Adult | 2015 |
The risks and benefits of switching antipsychotics: a case study approach.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertriglyceridemia; Long-Term Care; Male; Middle Aged; Olanzapine; Paroxetine; Psychotic Disorders; Risk Assessment; Schizophrenia; Thioridazine | 2009 |
Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study.
Topics: Adult; Aged; Antidepressive Agents; Biomarkers; Citalopram; Depression; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Treatment Outcome | 2009 |